BeiGene

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has granted marketing authorization for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. This marks the fourth indication in th.

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

The consensus price target hints at a 32.9% upside potential for BeiGene, Ltd. (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Trade

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the third quarter of 2023 and business highlights. “Our BeiGene team delivered another strong quarter across our global product portfolio, driven by the ongoing successful launch of BRUKINSA, where we continue to see rapid uptake across all approved indications, including CLL,” said John V. Oyler, Chairman.

BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a final draft guidance (FDG) recommending BRUKINSA® (zanubrutinib) for the treatment of eligible adult patients with: Untreated chronic lymphocytic leukemia (CLL) if there is a 17p deletion or TP53 mutation (high risk) or Untrea.

BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). No new safety signals.

BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS) by Blinded Independent Central Review (BICR), demonstrating statistically significant and clinically meaningful improvements in patients with resec.

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene's robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023. Highlights include the presentations of two late-breaking abstracts for tislelizumab, an anti-PD-1 antibody and the.

BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicul.

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Bristol-Myers

Kezar Life Sciences Inc

Novartis

Ocular Therapeutix

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved TEVIMBRA® (tislelizumab) as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. Additionally, the U.S. Food and Drug Administration (FDA) accepted for re.

BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®

BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis.

BeiGene regains rights for cancer drug after Novartis deal termination

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab). “We are excited to regain the global rights to TEVIMBRA, which enables us to build out our in-house solid tumor commercial capabilities and complements our deep pipeline presented at.

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11th, 2023 with a fireside chat at 9:20 am ET. A live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com, http://hkexir.beigene.com or https://sseir.beigene.

BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

BASEL, Switzerland, BEIJING, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights. “Our strong second quarter results highlight the continued execution of our global commercial teams and the success of our two cornerstone medicines, BRUKINSA and tislelizumab. As demonstrated by the growing prescriber use for patients with CLL, BRUKINSA.

BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results

Exelixis

Kura Oncology

Pfizer

AstraZeneca

Merck

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

7 Best Cancer Stocks to Invest in Now

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-.

BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two prior lines of therapy. BRUKINSA was.

BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SUZHOU, China & SHANGHAI--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. “With one of the industry's leading global oncology research teams, we are.

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder, Chairman and CEO, along with the Company's leadership team, will provide an update on BeiGene's deep and broad global innovation pipeline and platforms, and share insights on the C.

BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023

LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

NEW YORK , June 30, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially misleading business information to the investing public.

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

LOS ANGELES, CA / ACCESSWIRE / June 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE) on behalf of BeiGene stockholders. Our investigation concerns whether BeiGene has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On June 15, 2023, before the market opened, Morningstar released an artic.

News for BeiGene Stock (BGNE)